Glaukos (GKOS) Competitors $131.77 -0.48 (-0.36%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends GKOS vs. ZBH, SOLV, SNN, PEN, BLCO, INSP, PRCT, TMDX, AXNX, and NVSTShould you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), TransMedics Group (TMDX), Axonics (AXNX), and Envista (NVST). These companies are all part of the "medical equipment" industry. Glaukos vs. Zimmer Biomet Solventum Smith & Nephew Penumbra Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics TransMedics Group Axonics Envista Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, community ranking, profitability, analyst recommendations, valuation and dividends. Is ZBH or GKOS more profitable? Zimmer Biomet has a net margin of 14.27% compared to Glaukos' net margin of -47.39%. Zimmer Biomet's return on equity of 12.95% beat Glaukos' return on equity.Company Net Margins Return on Equity Return on Assets Zimmer Biomet14.27% 12.95% 7.55% Glaukos -47.39%-22.51%-12.36% Does the MarketBeat Community believe in ZBH or GKOS? Zimmer Biomet received 462 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 67.22% of users gave Zimmer Biomet an outperform vote while only 64.40% of users gave Glaukos an outperform vote. CompanyUnderperformOutperformZimmer BiometOutperform Votes89867.22% Underperform Votes43832.78% GlaukosOutperform Votes43664.40% Underperform Votes24135.60% Do analysts rate ZBH or GKOS? Zimmer Biomet currently has a consensus target price of $123.84, suggesting a potential upside of 15.45%. Glaukos has a consensus target price of $130.45, suggesting a potential downside of 0.94%. Given Zimmer Biomet's higher probable upside, research analysts plainly believe Zimmer Biomet is more favorable than Glaukos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 2 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.24Glaukos 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the media favor ZBH or GKOS? In the previous week, Zimmer Biomet had 23 more articles in the media than Glaukos. MarketBeat recorded 32 mentions for Zimmer Biomet and 9 mentions for Glaukos. Glaukos' average media sentiment score of 0.86 beat Zimmer Biomet's score of 0.17 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 6 Very Positive mention(s) 4 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, ZBH or GKOS? Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimmer Biomet$7.60B2.88$1.02B$5.2620.39Glaukos$314.71M22.99-$134.66M-$3.26-40.40 Do insiders and institutionals hold more shares of ZBH or GKOS? 88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by insiders. Comparatively, 6.4% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, ZBH or GKOS? Zimmer Biomet has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. SummaryZimmer Biomet beats Glaukos on 11 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Glaukos News Delivered to You Automatically Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GKOS vs. The Competition Export to ExcelMetricGlaukosSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$7.24B$4.45B$5.33B$19.25BDividend YieldN/A41.87%5.07%3.53%P/E Ratio-40.4044.53128.5743.31Price / Sales22.9960.861,489.0014.53Price / CashN/A49.3439.6220.89Price / Book13.924.264.765.40Net Income-$134.66M$11.52M$118.92M$985.39M7 Day Performance0.85%1.06%0.79%-0.71%1 Month Performance2.51%0.92%5.63%-0.97%1 Year Performance105.26%39.37%36.69%25.05% Glaukos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GKOSGlaukos3.6946 of 5 stars$131.77-0.4%$130.45-1.0%+89.5%$7.24B$314.71M-40.42780Upcoming EarningsInsider SellingZBHZimmer Biomet4.7966 of 5 stars$103.60+1.2%$123.94+19.6%+2.1%$21.31B$7.52B21.5818,000Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSOLVSolventum1.6144 of 5 stars$73.36+0.2%$64.33-12.3%N/A$12.67BN/A0.0022,000Upcoming EarningsSNNSmith & Nephew1.9164 of 5 stars$28.85+1.7%N/A+13.1%$12.61B$5.55B0.0018,452Analyst DowngradeNews CoverageGap UpPENPenumbra3.9 of 5 stars$208.92+2.1%$220.17+5.4%+20.2%$8.11B$1.06B614.474,200Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBLCOBausch + Lomb2.3267 of 5 stars$20.37-0.4%$20.27-0.5%+24.2%$7.17B$4.50B-15.6713,300Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageINSPInspire Medical Systems4.7114 of 5 stars$194.67-0.3%$219.58+12.8%+22.0%$5.81B$624.80M1,081.501,011Upcoming EarningsNews CoveragePRCTPROCEPT BioRobotics1.3709 of 5 stars$91.00+32.3%$86.40-5.1%+235.0%$4.73B$136.19M-44.17626Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews CoverageHigh Trading VolumeTMDXTransMedics Group4.2511 of 5 stars$126.24+0.9%$174.30+38.1%+116.6%$4.21B$241.62M3,156.00210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeAXNXAxonics3.8039 of 5 stars$70.24+0.0%$69.57-1.0%+35.9%$3.58B$408.81M-1,755.56610Upcoming EarningsShort Interest ↓Positive NewsNVSTEnvista4.3067 of 5 stars$19.23+1.8%$19.88+3.4%-8.9%$3.31B$2.57B-2.5012,800Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies ZBH Alternatives SOLV Alternatives SNN Alternatives PEN Alternatives BLCO Alternatives INSP Alternatives PRCT Alternatives TMDX Alternatives AXNX Alternatives NVST Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:GKOS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GKOS Stock Alerts